The information below contains an announcement for two COVID-19 and thrombosis research awards from the North American Thrombosis Forum (NATF). NATF recognizes many institutions and healthcare professionals around the globe are facing unprecedented challenges associated with the COVID-19 pandemic. We also believe that the healthcare and patient community will benefit from increased support for research and education during this crisis.

Thank you in advance for all that you are doing to improve the care of patients. NATF is proud to be able to support these efforts through this grants program. Please contact the NATF grants team at if you have any questions.

About NATF

NATF is a nonprofit organization dedicated to improving the lives of those affected by blood clots and related diseases. Through our comprehensive resources and innovative programming, we strive to educate patients and healthcare providers about thrombosis and its complications.

Since its inception, NATF’s accomplishments demonstrate the important role the organization plays in the field of thrombosis. The organization’s mission and areas of focus are reflected in its programmatic efforts. A multidisciplinary approach to thrombotic disease enhances education, awareness, advocacy, research, prevention, and diagnosis.


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus strain responsible for the COVID-19 pandemic. A significant proportion of patients become critically ill and commonly develop widespread systemic inflammation and multiorgan system involvement. The virus has also been associated with a surge of serious thrombotic events. Moreover, COVID-19 is has increased hospitalization rates. This uptick in hospitalizations— along with the rising incidence of thrombosis in these acute medically ill patients—underscores the need for more research.

Initial data suggest that the COVID-19 virus leads to a prothrombotic state through the release of proinflammatory cytokines that inappropriately activate the coagulation cascade. Coexisting endothelial dysfunction and injury in those with underlying comorbidities is believed to contribute to the high incidence of venous thromboembolism (VTE). International data have also consistently reported a high incidence of VTE and subsequent morbidity and mortality. However, these reports have been based on observational studies and more rigorous research has yet to be conducted.

Urgent Action Needed

To address this critical need, NATF is sponsoring two awards to support outstanding research and career development among clinicians and scientists in cardiovascular medicine, vascular medicine, hematology, pulmonology, internal medicine, hospital medicine, neurology, epidemiology, and critical care medicine at the early stage of their professional careers.

We are seeking thrombosis-focused applicants who will contribute to understanding the pathogenesis, diagnosis, prevention, treatment, and management (including critical care management) of COVID-19-associated thrombosis. Given the urgency of this issue, we are looking for innovative, highly impactful proposals that can be completed within 9-12 months.

NATF will award two grants in the amount of $25,000 each (including up to 10% of institutional indirect costs). Applications for funding are due by June 24, 2020.

NATF will announce the awards by July 15, 2020.


Applicant Criteria

    • The candidate must hold a post-baccalaureate Ph.D. degree or equivalent, or a doctoral- level clinical degree, such as M.D., D.O., Pharm.D., or Ph.D. in nursing, public health, or other clinical health science
    • This program is limited to early-career investigators. Applicants must submit evidence of employment at a qualifiedinstitution. We define early career professionals as within 5 years of completing the ultimate stage of training. Fellows are eligible.
    • NATF supports diversity and inclusion and encourages applications from women, military veterans, people with disabilities, members of the LGBTQ community, underrepresented racial and ethnic groups in the sciences, and those who have experienced varied and nontraditional career trajectories.
    • Candidate must be a US Citizen or Green Card holder.

Sponsoring Institution Criteria

This award is limited to U.S.-based institutions, including medical and osteopathic schools, schools of public health, pharmacy schools, nursing schools, universities and colleges, hospitals, and others that can demonstrate the ability to conduct the proposed research.

Submission Requirements

    1. A six-page proposal (11 pt. Arial font, 1.5 line spacing, margins of at least 0.75” on all sides) that addresses the following items:

      1.1 What specific question is being addressed?

      1.2 What population(s) is being studied?

      1.3 What is the anticipated actionable outcome?

      1.4 Details of the study design

      1.5 Timeline of the proposed project

      1.6 How will the funds be used?

    2. Principal Investigator CV or NIH Biosketch (CV or biosketch of co-investigators, if any, are also required)
    3. Name and CV of mentor
    4. Letter of support from the Chairman of the Department indicating the feasibility of the proposed project to be carriedout
    5. Proof of nonprofit status of the awardees institution
    6. An additional one-page reference document is permitted (optional).

Applicants must combine the above into a single PDF document. Applications should be emailed to with the subject heading “COVID-19 Grant.” Applicants will receive an email confirmation upon submission indicating that all documents have been received. Incomplete applications will not be considered.

Additional Requirements

  • The awardee must commit to submitting their research for publication in a peer-reviewed medical journal. The awardee must acknowledge NATF as a source of funding in any publications arising from work supported by these grants.
  • The awardee must also commit to presenting their research at one 2021 NATF educational event (either live or virtual).
  • All institutional assurances (IRB and/or IACUC protocols, etc.) must be submitted to NATF prior to release of funds.